AI-Designed CRISPR Enables Hypoimmune iPSC Engineering for Off-the-Shelf Cell Therapy
Induced pluripotent stem cells (iPSCs) are rapidly advancing regenerative medicine and cell therapy because they can differentiate into multiple human cell types. However, immune rejection remains a major barrier to developing scalable allogeneic cell therapies. In a recent webinar, Dr. Luke Ren from REPROCELL presented how the company is using StemEdit, its advanced gene editing…









